ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
Dow Jones
42,840.26
1.18%
US Dollar vs MXN
20.0779
0.00%
Brent Oil
72.72
0.00%
Bitcoin
98,214.28
0.47%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Cardiol Therapeutics Inc (CRDL) Cotización

Cardiol Therapeutics Inc

Cardiol Therapeutics Inc (CRDL)

Cordel Group Plc
Cardiol Therapeutics Inc
1.28
-0.03
(-2.29%)
Cerrado 21 Diciembre 3:00PM
Delayed by 15 minutes
1.28
-0.005
(-0.39%)
Fuera de horario: 6:22PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
1.28
Postura de Compra
1.28
Postura de Venta
9.00
Volume Operado de la Acción
406,184
1.28 Rango del Día 1.44
0.7912 Rango de 52 semanas 3.12
Capitalización de Mercado [m]
104.452M
Precio Anterior
1.31
Precio de Apertura
1.44
Hora
93
@
1.31
Última hora de negociación
Volumen financiero
US$ 533,556
Precio Promedio Ponderado
1.3136
Volumen promedio (3 m)
479,169
Acciones en circulación
81,603,422
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-5.37
Beneficio por acción (BPA)
-0.34
turnover
-
Beneficio neto
-28.13M

Acerca de Cardiol Therapeutics Inc

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solut... Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. Mostrar más

Sector
Coml Physical, Biologcl Resh
Industria
Coml Physical, Biologcl Resh
Sede
Oakville, Ontario, Can
Fundado
-
Cardiol Therapeutics Inc is listed in the Coml Physical, Biologcl Resh sector of the NASDAQ with ticker CRDL. The last closing price for Cardiol Therapeutics was US$1.31. Over the last year, Cardiol Therapeutics shares have traded in a share price range of US$ 0.7912 to US$ 3.12.

Cardiol Therapeutics currently has 81,603,422 shares in issue. The market capitalisation of Cardiol Therapeutics is US$106.90 million. Cardiol Therapeutics has a price to earnings ratio (PE ratio) of -5.37.

CRDL Últimas noticias

Más noticias

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics...

19 Diciembre 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

18 Noviembre 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

14 Noviembre 2024
Edgar (US Regulatory)

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL...

13 Noviembre 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

22 Octubre 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

11 Octubre 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

10 Octubre 2024
Edgar (US Regulatory)

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

09 Octubre 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

09 Octubre 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

08 Octubre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.08-5.882352941181.361.45991.274051851.33689513CS
4-0.33-20.49689440991.611.6551.273740991.45153334CS
12-0.84-39.62264150942.122.241.274791691.75209632CS
26-0.73-36.31840796022.012.631.273941531.90363708CS
520.4248.83720930230.863.120.79124034951.90383538CS
156-0.72-3623.120.452739841.54312653CS
260-1.35-51.33079847912.634.960.453334852.03153832CS

CRDL - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Cardiol Therapeutics?
El precio actual de las acciones de Cardiol Therapeutics es US$ 1.28
¿Cuántas acciones de Cardiol Therapeutics están en circulación?
Cardiol Therapeutics tiene 81,603,422 acciones en circulación
¿Cuál es la capitalización de mercado de Cardiol Therapeutics?
La capitalización de mercado de Cardiol Therapeutics es USD 106.9M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Cardiol Therapeutics?
Cardiol Therapeutics ha negociado en un rango de US$ 0.7912 a US$ 3.12 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Cardiol Therapeutics?
El ratio precio/beneficio de Cardiol Therapeutics es -5.37
¿Cuál es la moneda de reporte de Cardiol Therapeutics?
Cardiol Therapeutics presenta sus resultados financieros en CAD
¿Cuál es el último beneficio anual de Cardiol Therapeutics?
El último beneficio anual de Cardiol Therapeutics es CAD -28.13M
¿Cuál es la dirección registrada de Cardiol Therapeutics?
La dirección registrada de Cardiol Therapeutics es 2265 UPPER MIDDLE ROAD EAST, SUITE 602, OAKVILLE, ONTARIO, L6H 0C3
¿En qué sector industrial opera Cardiol Therapeutics?
Cardiol Therapeutics opera en el sector COML PHYSICAL, BIOLOGCL RESH

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.32M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
305.1M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
292.16M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
287.21M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
277.63M

CRDL Discussion

Ver más
MahinAgency MahinAgency 4 semanas hace
NASDAQ: $CRDL SHORT SQUEEZE ALERTS

Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 4 semanas hace
NASDAQ: $CRDL

Cardiol Therapeutics MAvERIC-Pilot Study Results:

Safety: High tolerability and 95% compliance.

Next Steps: Data supports advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
👍️0
MahinAgency MahinAgency 4 semanas hace
A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 4 semanas hace
NASDAQ: $CRDL

Advancement: Results support Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials, expanding accessibility to non-immunosuppressive oral therapy.

Short Squeeze Alerts $CRDL, BIG OPPORTUNITY
👍️0
MahinAgency MahinAgency 4 semanas hace
NASDAQ: $CRDL

Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 4 semanas hace
NASDAQ: $CRDL Pick Up This Morning Short Sueeze Aler

 MAvERIC-Pilot Results:
Safety: High tolerance, 95% compliance.
Next Steps: Advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
👍️0
MahinAgency MahinAgency 4 semanas hace
NASDAQ: $CRDL MAvERIC-Pilot Study:

Efficacy: Significant reductions in pericarditis pain (mean score 5.8 to 1.5) and inflammation (CRP normalized in 80% of patients). Episodes dropped from 5.8/year to 0.9 during the trial.

👍️0
MahinAgency MahinAgency 1 mes hace
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
👍️0
MahinAgency MahinAgency 1 mes hace
INSIDER BUYING : Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
👍️0
MahinAgency MahinAgency 1 mes hace
$CRDL Here are the MAvERIC-Pilot study results that we’ve been waiting for! 

❤️Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week study!

❤️Episodes of pericarditis per year substantially reduced 

❤️MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2
and the Phase III MAVERIC-3 clinical trials

Congratulations to all long term shareholders! 
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL BIG NEWS:

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
👍️0
MahinAgency MahinAgency 1 mes hace
Breaking News: NASDAQ: $CRDL unveils groundbreaking results for CardiolRx™ at the American Heart Association Conference! 📷 Rapid pain relief, 85% fewer recurrences, and lasting inflammation reduction.
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Valued at $9 per share, assuming $609M in sales

Valued at $1 per share, assuming $132M in sales
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL RED TO GREEN, Looks Good

Cardiol Therapeutics Inc Today at 11:15am EST Dr. Allen Luis MayoClinic will present the Pericarditis full clinical data at #AHA2024
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL SHORT SQUEEZE ALERTS, STAY TUNED

Addressing urgent unmet medical needs: CardiolRx™ targets acute myocarditis, a life-threatening condition with no FDA-approved treatments
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

 Valued at $9 per share, assuming $609M in sales by 2033

Valued at $1 per share, assuming $132M in sales by 2033
👍 1
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

Recently raised $13.5 million to fund developments?, SHORT SQUEEZE ALERTS
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL lets See Red To Green, 

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

The company recently raised $13.5 million
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL The company recently raised $13.5 million, ensuring financial backing for ongoing clinical developments and corporate growth
👍️0
MahinAgency MahinAgency 1 mes hace
Picked up NASDAQ: $CRDL this morning…low float runner on news incoming… Short Squeeze Alerts

The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis
👍️0
tw0122 tw0122 1 mes hace
30 million shares offering at .26 October 30th
👍️0
MahinAgency MahinAgency 1 mes hace
H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
👍️0
MahinAgency MahinAgency 1 mes hace
$CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL SHORT SQUEEZE ALERTS

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price,aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 1 mes hace
Key Points:

Rating & Price Target: H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.
New Trial: MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis (RP) patients post-IL-1 blocker therapy.
Market Advantage: CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.
Strategic Expansion: By targeting unmet needs in the RP market, CardiolRx is positioned to broaden its market potential.
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

Recently raised $13.5 million to fund developments?
👍️0
MahinAgency MahinAgency 1 mes hace
Big coming Next week 💃💃💃💃
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL
ARCHER trial completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales 

Promising early results, potential approval by 2027, targeting $609M peak sales

👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60

$CRDL BIG SHORT SQUEEZE 
👍️0
tw0122 tw0122 1 mes hace
Chart looking good $2.07 next targets $4
👍️0
glenn1919 glenn1919 1 mes hace
CRDL........................https://stockcharts.com/h-sc/ui?s=CRDL&p=W&b=5&g=0&id=p86431144783
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Cardiol had around $21 million in cash at the end of Q1 


👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL
 Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis.

The 12-month price target is $10
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 1 mes hace
NASDAQ: CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million
👍️0
MahinAgency MahinAgency 2 meses hace
NASDAQ: $CRDL CEO Investment: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
👍️0
MahinAgency MahinAgency 2 meses hace
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 2 meses hace
NASDAQ: $CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

👍️0
MahinAgency MahinAgency 2 meses hace
NASDAQ: $CRDL A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 2 meses hace
Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 2 meses hace
$CRDL Insider Buying: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each
👍️0
MahinAgency MahinAgency 2 meses hace
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities
👍️0
MahinAgency MahinAgency 2 meses hace
NASDAQ: $CRDL 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

👍️0
MahinAgency MahinAgency 2 meses hace
NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

Cardiol sets a 12-month price target of $10
👍️0
MahinAgency MahinAgency 2 meses hace
NASDAQ: $CRDL Short Squeeze Allerts 

A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 2 meses hace
Volume looks GOOD 💃💃🚀
👍️0
MahinAgency MahinAgency 2 meses hace
NASDAQ: $CRDL Valuation: The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

PICK UP $CRDL THIS MORNING

👍️0

Su Consulta Reciente

NASDAQ
CRDL
Cardiol Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados